Search Results
Mar 06, 2026, 08:00 ET Kimberly-Clark Appoints Francesco Tinto as Chief Information & GBS Officer
Information & GBS Officer, Tinto will lead Kimberly-Clark's Information Technology and GBS organizations. "Francesco brings a rare combination of technology leadership and operational expertise that will strengthen our capabilities as we advance our Powering Care strategy,"
More news about: Kimberly-Clark Corporation
Mar 06, 2026, 08:00 ET DiligenceSquared Raises $5M to Bring AI-Driven Commercial Due Diligence to Private Equity
PowerPoint slides."Hansen's view is shared by early investors who see the category as ripe for modernization and scale."This team brings a rare combination of deep domain expertise, technical strength, and firsthand experience purchasing and relying on traditional commercial due diligence,"
More news about: DiligenceSquared
Mar 06, 2026, 08:00 ET Aisa Pharma Announces Encouraging Results from Phase 2 RECONNOITER Trial of AISA-021 (Cilnidipine) in Patients with Systemic Sclerosis-Associated Raynaud's Phenomenon
is a clinical-stage biopharmaceutical company dedicated to developing and commercializing new disease-modifying treatments for patients with serious rare diseases. The Company's lead program, AISA-021, is an investigational oral dual calcium channel inhibitor designed to promote vasodilation and support
More news about: Aisa Pharma
Mar 06, 2026, 07:45 ET Guiyang Confucius Academy Spring Festival Cultural Fair: A Global Invitation to Traditional Chinese Culture
distinctive Sino‑Western fusion in the shows and planned to return next year. Gao Fang appreciated the rich folk activities, which offered children a rare chance to experience traditional customs in the city. Zhang Yuhan, thrilled by Miao silver pattern painting, described the event as lively and full
More news about: Huanqiu.com
Mar 06, 2026, 07:00 ET Kedrion Activates Nationwide Distribution Network for QIVIGY® in the U.S.
Kedrion Biopharma Kedrion Biopharma collects and fractionates blood plasma to produce and distribute plasma-derived therapies for rare, ultra-rare, and debilitating conditions like Coagulation and Neurological Disorders, Immunodeficiencies, and Rh sensitization. We employ approximately 5,200
More news about: Kedrion Biopharma
Mar 06, 2026, 06:02 ET 15 Top Press Releases from February
by Black Promoters Collective, the iconic duo returns to the stage for the first time since 2016, joined by Raheem DeVaughn and Teedra Moses for a rare, soulful R&B-forward live experience.Read more of
More news about: PR Newswire
Mar 06, 2026, 04:20 ET Foresee Pharmaceuticals Welcomes Positive CHMP Opinion Recommending Approval of CAMCEVI 21mg, 3-month strength in the European Union for Advanced Prostate Cancer
with derived drug products targeting specialty markets and secondly, its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs.Foresee's product portfolio includes late and early-stage programs. CAMCEVI 42 mg, for the treatment
More news about: Foresee Pharmaceuticals Co., Ltd.
Mar 05, 2026, 23:41 ET CGTN: How China sets stage for strong start to its next Five-Year Plan, opens global opportunities
prevailing short-termism, China's 15th FYP, a draft outline of which was submitted to the NPC session for review on Thursday, continues to provide a rare degree of strategic confidence and consistency.Over the next five years, China expects to keep its GDP growth within an appropriate range, which
More news about: CGTN
Mar 05, 2026, 23:38 ET Exosome Diagnostic and Therapeutics Market to Reach USD 401.70 Million by 2032 Amid Rapid Advances in Liquid Biopsy, Precision Medicine, and Exosome-Based Drug Delivery - Credence Research
France are central to regional market expansion, supported by research collaborations and increasing use of exosome-based technologies in oncology and rare disease applications.Market Challenges Include High Development Costs, Regulatory Complexity, and Technical Standardization IssuesDespite
More news about: Credence Research Inc.
Mar 05, 2026, 23:27 ET CGTN: How China sets stage for strong start to its next Five-Year Plan, opens global opportunities
prevailing short-termism, China's 15th FYP, a draft outline of which was submitted to the NPC session for review on Thursday, continues to provide a rare degree of strategic confidence and consistency.Over the next five years, China expects to keep its GDP growth within an appropriate range, which
More news about: CGTN
Mar 05, 2026, 20:49 ET Renforcer l'autonomie de la communauté SBMA : AnnJi anime le forum des patients et des familles et communique les avancées scientifiques concernant l'AJ201 lors de la conférence KDA 2026
(SBMA)La maladie de Kennedy, également connue sous le nom d'amyotrophie bulbo-spinale (SBMA), est une maladie neuromusculaire dégénérative héréditaire rare et grave. Elle se caractérise par la dégénérescence progressive des neurones moteurs inférieurs de la moelle épinière, du tronc cérébral et des muscles
More news about: AnnJi Pharmaceutical Co., Ltd.
Mar 05, 2026, 18:40 ET San Diego Zoo Safari Park Celebrates Official Opening of Elephant Valley
diverse ecosystems, specifically the vast savanna and grasslands. More than 350 individual plants have been grown for Elephant Valley, representing rare and endangered African plants.Elephant Valley bridges the vital work happening in San Diego to the collaborative elephant conservation initiatives
More news about: San Diego Zoo Wildlife Alliance
Mar 05, 2026, 18:03 ET Atlas Ocean Voyages Highlights Limited Availability for 2026 Mediterranean Epicurean Expeditions Featuring Included Atlas Immersive Experiences
selection of elegant canapés—such as smoked salmon and local cheeses—paired with Turkish wines, beer, and refreshments. This four-hour immersion offers a rare opportunity to witness one of the world's most iconic archaeological sites in the soft evening light, free from daytime crowds.Civitavecchia
More news about: Atlas Ocean Voyages
Mar 05, 2026, 17:31 ET Global Companion Diagnostics Market to Register Immense Growth at a CAGR of ~12% by 2032 | DelveInsight
diagnostics. Adoption is especially high in Western Europe, where healthcare systems increasingly integrate companion diagnostics for oncology and rare diseases.Asia-PacificAsia-Pacific exhibits the fastest growth in the global market. Factors such as improving
More news about: DelveInsight Business Research, LLP
Mar 05, 2026, 16:59 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadlines - RARE
-- Pomerantz LLP announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NASDAQ: RARE). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Mar 05, 2026, 16:57 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Inovio Pharmaceuticals, Inc. and Certain Officers - INO
for purported optimal effect. Inovio's lead product candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis ("RRP"), a life-long, rare disease of the respiratory tract caused by HPV infection. At all relevant times, Defendants touted the prospects of the U.S. Food and Drug Administration
More news about: Pomerantz LLP
Mar 05, 2026, 16:30 ET Azitra, Inc. Announces Cancellation of 2026 Special Meeting of Stockholders
for precision dermatology. Azitra's lead program, ATR-12, uses an engineered strain of S. epidermidis designed to treat Netherton syndrome, a rare, chronic skin disease with no approved treatment options. Netherton syndrome may be fatal in infancy with those living beyond a year having profound
More news about: Azitra, Inc.
Mar 05, 2026, 16:03 ET Viking Therapeutics to Participate at Upcoming Investor Conferences
of internally developed dual amylin and calcitonin receptor agonists (or DACRAs) for the treatment of obesity and other metabolic disorders. In the rare disease space, Viking is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential
More news about: Viking Therapeutics, Inc.
Mar 05, 2026, 16:01 ET AMGEN TO PRESENT AT THE LEERINK PARTNERS 2026 GLOBAL HEALTHCARE CONFERENCE
Wednesday, March 11, 2026. Peter Griffith, executive vice president and chief financial officer at Amgen, and Jasper van Grunsven, senior vice president of rare disease at Amgen, will participate in a fireside chat at the conference. The webcast will be broadcast over the internet simultaneously and will be
More news about: Amgen
Mar 05, 2026, 15:55 ET Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line
treatment discontinuation and were effectively managed using standard guidelines.3 Immune effector cell-associated neurotoxicity syndrome was rare and occurred in 1.1% of patients.3 Serious adverse events occurred in 70.7% of patients compared to 62.4% of patients treated with the control
More news about: Johnson & Johnson
Mar 05, 2026, 15:38 ET REMADE® Conference To Feature 50 Innovations to Increase the Reuse, Remanufacturing, Recovery and Recycling of Critical and Key Materials
several high-level keynote speakers and expert panel discussions in addition to the 50 paper presentations. Panel topics include critical minerals and rare earths recovery and recycling; textiles recycling; and the importance of university-based research and innovation.Keynoters include:Paul Ekins,
More news about: REMADE Institute
Mar 05, 2026, 14:49 ET SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Texas Mineral Resources Corp. (OTCQB: TMRC)
TMRC) related to its sale to USA Rare Earth, Inc. for 3,823,328 shares of USA Rare Earth common stock. Is it a fair deal?
More news about: Monteverde & Associates PC
Mar 05, 2026, 14:00 ET Marina Pointe's Luna Tower Offers Tampa Bay Waterfront Buyers an Early-Cycle Opportunity in a Community Already Alive
boat slip accommodating yachts from 40 to 90 feet.Centrally located minutes from downtown Tampa and St. Petersburg, Marina Pointe offers the rare balance of coastal sophistication and metropolitan convenience. For more information, visit MarinaPointe.com.The three Marina Pointe
More news about: Marina Pointe
Mar 05, 2026, 13:03 ET Neuspera Medical Announces 12-Month Pivotal Trial Results for the Company's Integrated Sacral Neuromodulation System for Urinary Urge Incontinence
maintained an excellent safety profile, with zero serious device-related adverse events (AEs) and zero infections through 12 months. Device-related AEs were rare, generally mild, and resolved quickly, with incident rates of 0-3% for all AE categories. Dr. Pezzella also presented promising initial data using
More news about: Neuspera Medical
Mar 05, 2026, 12:54 ET Norgine annuncia un nuovo investimento di 23 milioni di sterline nell'ambito di un impegno complessivo di oltre 50 milioni per l'espansione della produzione di farmaci in Galles
esperienza, con competenze specialistiche in ingegneria e progettazione di sistemi, a supporto della produzione di farmaci per patologie gastrointestinali, rare e specialistiche, sia dal portafoglio di Norgine che da partner selezionati in licenza in Europa e non solo.Investire nelle competenze e restituire
More news about: Norgine B.V.